IGC Pharma Inc (IGC)
0.3561
0.00 (0.00%)
USD |
NYAM |
Nov 22, 11:30
IGC Pharma Enterprise Value: 25.89M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 25.89M |
| November 20, 2024 | 24.40M |
| November 19, 2024 | 25.16M |
| November 18, 2024 | 25.77M |
| November 15, 2024 | 24.84M |
| November 14, 2024 | 26.29M |
| November 13, 2024 | 27.03M |
| November 12, 2024 | 28.10M |
| November 11, 2024 | 28.02M |
| November 08, 2024 | 28.17M |
| November 07, 2024 | 28.33M |
| November 06, 2024 | 27.62M |
| November 05, 2024 | 27.79M |
| November 04, 2024 | 27.47M |
| November 01, 2024 | 28.12M |
| October 31, 2024 | 28.47M |
| October 30, 2024 | 29.15M |
| October 29, 2024 | 28.94M |
| October 28, 2024 | 29.63M |
| October 25, 2024 | 28.93M |
| October 24, 2024 | 28.48M |
| October 23, 2024 | 28.85M |
| October 22, 2024 | 30.09M |
| October 21, 2024 | 29.24M |
| October 18, 2024 | 28.52M |
| Date | Value |
|---|---|
| October 17, 2024 | 29.29M |
| October 16, 2024 | 29.78M |
| October 15, 2024 | 27.33M |
| October 14, 2024 | 26.61M |
| October 11, 2024 | 26.57M |
| October 10, 2024 | 26.94M |
| October 09, 2024 | 26.36M |
| October 08, 2024 | 26.55M |
| October 07, 2024 | 27.02M |
| October 04, 2024 | 26.98M |
| October 03, 2024 | 26.33M |
| October 02, 2024 | 28.13M |
| October 01, 2024 | 28.12M |
| September 30, 2024 | 31.31M |
| September 27, 2024 | 25.09M |
| September 26, 2024 | 24.78M |
| September 25, 2024 | 24.13M |
| September 24, 2024 | 24.31M |
| September 23, 2024 | 24.27M |
| September 20, 2024 | 24.93M |
| September 19, 2024 | 24.69M |
| September 18, 2024 | 24.03M |
| September 17, 2024 | 24.89M |
| September 16, 2024 | 24.90M |
| September 13, 2024 | 25.26M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-3.279M
Minimum
Mar 18 2020
138.25M
Maximum
Feb 10 2021
31.32M
Average
21.82M
Median
Aug 06 2020
Enterprise Value Benchmarks
| CEL-SCI Corp | 36.79M |
| AIM ImmunoTech Inc | 9.017M |
| NovaBay Pharmaceuticals Inc | 2.798M |
| Protalix BioTherapeutics Inc | 94.82M |
| Palatin Technologies Inc | 15.96M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.717M |
| Revenue (Quarterly) | 0.412M |
| Total Expenses (Quarterly) | 2.172M |
| EPS Diluted (Quarterly) | -0.02 |
| Gross Profit Margin (Quarterly) | 48.06% |
| Profit Margin (Quarterly) | -416.7% |
| Earnings Yield | -50.55% |
| Normalized Earnings Yield | -35.83 |